Switch to injectable cabotegravir-rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial. (linkinghub.elsevier.com)

Authors: Bwakura-Dangarembizi M … Pett S Journal: The Lancet Published: 2026-09-17 DOI: https://doi.org/10.1016/S0140-6736(26)01537-0